生物制剂与免疫调节剂在乳房手术中的安全性:回顾性队列分析
本研究利用TriNetX数据库回顾性分析211105例乳房再造或隆乳患者,其中4024例术前6个月内暴露于生物制剂或免疫调节剂。倾向评分匹配后两组各3980例,各时间点并发症率无显著差异,术前暴露未增加术后并发症风险。
要点
- 术前6个月内使用生物制剂或免疫调节剂未显著增加乳房手术后并发症。
- 匹配后两组在30天、90天和6个月并发症率相当(p>0.05)。
- 适当患者继续这些治疗似乎是安全的,或可减少不必要的中断。
核心结论
- 术前使用生物制剂或免疫调节剂与乳房再造或隆乳术后手术并发症显著增加无关。
研究设计与样本
- 回顾性队列分析,使用TriNetX数据库,纳入211105例乳房再造或隆乳患者。
- 按术前6个月内生物制剂或免疫调节剂暴露分层,倾向评分匹配(1:1)控制人口学和临床协变量。
- 匹配后生物制剂暴露组和对照组各3980例。
主要发现
- 匹配后两组在30天、90天和6个月并发症率相当(p>0.05)。
- 生物制剂暴露与伤口、感染、植入物修正或再入院并发症风险增加无关。
临床怎么用
- 适当患者可继续术前生物制剂或免疫调节剂治疗,或减少不必要的中断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic and targeted immune-modulating agents are increasingly used to manage autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As more patients receiving these therapies undergo elective breast augmentation and implant-based reconstruction, the effect of biologic exposure on postoperative outcomes remains unclear. OBJECTIVES: This study evaluated whether preoperative use of biologic or immune-modulating agents is associated with increased complications following reconstructive and aesthetic breast surgery procedures. METHODS: A retrospective cohort analysis was performed using the TriNetX database. Patients who underwent breast reconstruction or augmentation were identified by Current Procedural Terminology codes and stratified by preoperative exposure to biologic or immune-modulating agents within six months of surgery. Agents included tumor necrosis factor-α, interleukin, Janus kinase, mammalian target of rapamycin, and calcineurin inhibitors, among others. Propensity score matching (1:1) controlled for demographic and clinical covariates. Postoperative complications were assessed at 30-days, 90-days, and 6-months and included wound dehiscence, infection, seroma or hematoma, implant revision, and hospital readmission. RESULTS: Among 211,105 patients, 4,024 had biologic exposure and 207,081 were controls. After propensity score matching, 3,980 patients remained in each cohort. Complication rates were comparable between groups at all timepoints (p > 0.05). Biologic exposure was not associated with increased risk of wound, infectious, implant revision, or hospital readmission complications. CONCLUSIONS: Preoperative biologic or immune-modulating therapy was not associated with a significant increase in postoperative surgical complications after breast reconstruction or augmentation procedures. Continuing these therapies in appropriate patients appears safe and may reduce unnecessary treatment interruptions.
引用
- Chaudhry AS, Tian W, Adam TH, et al. Safety of Biologic and Immune-modulating Agents in Breast Surgery Procedures: A Retrospective Cohort Analysis. Aesthet Surg J. 2026. PMID: 42324957. doi:10.1093/asj/sjag112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。